Skip to main contentSkip to footer
Evidence Strategy

R&D Planning & Evidence Exploration

when to generate it, and how it will be used to support downstream market access, reimbursement, policy and commercial outcomes.

50+
years' MBS, PBAC and PL experience
100+
submissions to the MSAC, PBAC and MDHTAC
50+
early-stage feasibility assessments
3
former MSAC/PBAC evaluators

Early decisions have long-term consequences

Choices made at this stage can either enable or constrain future PBAC, MSAC, Prescribed List and policy funding pathways.

Pulse Economics works with pharmaceutical, biotech, medtech and diagnostics organisations to design forward-looking R&D and evidence strategies.

Our advice is grounded in first-hand PBAC and MSAC evaluation experience, giving us a clear view of how early evidence choices are later interrogated, stress-tested and challenged.

We help clients move beyond:

“What evidence will decision-makers ultimately need?”

R&D planning & evidence support in practice

HTA-aligned evidence gap assessments

Structured mapping of your current evidence base against what PBAC and MSAC will require at submission.

Clinical development pathways & endpoints

Strategic advice ensuring your trial design generates endpoints that will withstand HTA scrutiny.

Early health economic framework development

Establishing value frameworks early before clinical development locks assumptions.

Evidence exploration & comparator positioning

Rigorous literature review to inform comparator selection and clinical context.

Burden of disease & outcomes scoping

Epidemiological assessments quantifying disease prevalence and socioeconomic impact.

Real-world evidence & utility studies

Assessments leveraging real-world data alongside utility studies quantifying quality of life impact.

Ready to accelerate your evidence journey?

Every successful reimbursement outcome begins with evidence planned with the end decision in mind.

Connect With An Access Strategist →

Frequently Asked Questions

It’s the plan for what clinical, economic and real-world evidence needs to be generated and when, so a submission can withstand MSAC, PBAC or Prescribed List scrutiny down the track. Getting this right early avoids a common trap: running a trial that produces clinically valid data but the wrong endpoints for reimbursement.
Choices made at the R&D stage, such as trial endpoints, comparators and what real-world data gets collected, either enable or constrain the funding pathways available later. Our team includes former PBAC and MSAC evaluators, so our advice reflects how evidence is actually interrogated at committee level.
It’s a structured comparison of the evidence a sponsor already has against what MSAC, MDHTAC or PBAC will expect at submission. Gaps are identified while there’s still time to close them through trial design or extra data collection, rather than after a rejected or deferred submission.
Earlier than most sponsors assume: ideally alongside study design, not after data readout. Setting the value framework and health economic assumptions before clinical development locks them in means the study is built to generate the inputs a cost-effectiveness or cost-utility model will need.
Clinical evidence shows a product works. HTA-ready evidence shows it works in a way MSAC, MDHTAC or PBAC can compare, cost and defend against a cost-effectiveness or budget impact test. That gap is what many R&D teams don’t plan for. It’s also where early evidence exploration and comparator positioning pay off.